Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review (Q30703364)

26 June 2017

1 reference

0 references

1 reference

title

Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review (English)

1 reference

26 June 2017

1 reference

1 reference

A G Marson

1 reference

26 June 2017

J L Hutton

1 reference

26 June 2017

J P Leach

1 reference

26 June 2017

S Castillo

1 reference

26 June 2017

D Schmidt

1 reference

26 June 2017

S White

1 reference

26 June 2017

R Chaisewikul

1 reference

26 June 2017

M Privitera

1 reference

26 June 2017

D W Chadwick

1 reference

26 June 2017

publication date

1 September 2001

1 reference

26 June 2017

1 reference

26 June 2017

1 reference

26 June 2017

1 reference

26 June 2017

page(s)

259-270

1 reference

Quality of life of people with epilepsy: a European study

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900287-X

7 January 2021

Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900287-X

7 January 2021

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900287-X

7 January 2021

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900287-X

7 January 2021

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900287-X

7 January 2021

Remission of epilepsy: results from the National General Practice Study of Epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900287-X

7 January 2021

Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900287-X

7 January 2021

How easy are randomized controlled trials in epilepsy to find on Medline? The sensitivity and precision of two Medline searches

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900287-X

7 January 2021

The new antiepileptic drugs: a systematic review of their efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900287-X

7 January 2021

Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900287-X

7 January 2021

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2801%2900287-X

7 January 2021

10.1016/S0920-1211(01)00287-X

Identifiers

DOI

1 reference

26 June 2017

1 reference